Menu
Search
|

Menu

Close
X

Tetraphase Pharmaceuticals Inc TTPH.OQ (NASDAQ Stock Exchange Global Select Market)

2.12 USD
-- (--)
As of Feb 16
chart
Previous Close 2.12
Open --
Volume --
3m Avg Volume 192,649
Today’s High --
Today’s Low --
52 Week High 9.69
52 Week Low 2.10
Shares Outstanding (mil) 51.59
Market Capitalization (mil) 109.38
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
5
FY15
12
EPS (USD)
FY17
-2.259
FY16
-2.110
FY15
-2.370
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
13.29
8.59
Price to Book (MRQ)
vs sector
0.73
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
0.00
15.32
LT Debt to Equity (MRQ)
vs sector
0.00
11.95
Return on Investment (TTM)
vs sector
-73.57
13.59
Return on Equity (TTM)
vs sector
-73.64
15.20

EXECUTIVE LEADERSHIP

Leonard Patrick Gage
Chairman of the Board of Directors, Since 2011
Salary: --
Bonus: --
Guy Macdonald
President and Chief Executive Officer, Director, Since 2008
Salary: $420,000.00
Bonus: --
Christopher Watt
Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance, Since 2017
Salary: --
Bonus: --
Kamalam Unninayar
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Maria Stahl
Senior Vice President, General Counsel, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

480 Arsenal St Ste 110
WATERTOWN   MA   02472-2891

Phone: +1617.7153600

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

SPONSORED STORIES